Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer
- 1 May 2021
- journal article
- letter
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (13), 1506-1507
- https://doi.org/10.1200/jco.20.03215
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)Journal of Clinical Oncology, 2020
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast CancerJournal of Clinical Oncology, 2017
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 YearsThe New England Journal of Medicine, 2017
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine TherapyJournal of Clinical Oncology, 2017
- Extending Aromatase-Inhibitor Adjuvant Therapy to 10 YearsThe New England Journal of Medicine, 2016
- Statistical controversies in clinical research: long-term follow-up of clinical trials in cancerAnnals of Oncology, 2015
- Strategies for developing Ki67 as a useful biomarker in breast cancerThe Breast, 2015
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013